Dr Marco Herold is a Laboratory Head in the Molecular Genetics of Cancer Division at WEHI. He is an expert in developing novel pre-clinical models of human diseases. Dr Herold has brought the CRISPR/Cas9 genome editing technology to WEHI, where he is also heading the CRISPR laboratory. The aim of the laboratory is to generate genome modified pre-clinical models.
Dr Herold’s PhD at the University of Würzburg (Germany) addressed key questions in apoptosis and cancer. After his PhD, Dr Herold moved into the field of mouse genetics, and has generated more than 15 different pre-clinical rodent models, facilitating research into diseases including cancer and type 2 diabetes. His major research interest is in the identification of novel genes in apoptosis, and in finding new targets for cancer therapy.
